Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Factorial Design, Randomized Controlled Study to Explore the Efficacy and Safety of Finerenone and Empagliflozin, Alone or in Combination, in Delaying Renal Function Progression in High-Risk CKD Patients After Radical Nephrectomy for Renal Cell Carcinoma

NCT06818305 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.

NCT NCT06818305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06818305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Factorial Design, Randomized Controlled Study to Explore the Efficacy and Safety of Finerenone and Empagliflozin, Alone or in Combination, in Delaying Renal Function Progression in High-Risk CKD Patients After Radical Nephrectomy for Renal Cell Carcinoma
Lead sponsor
Jinling Hospital, China
Phase
Phase 2
Overall status
Terminated
Start date
January 1, 2025
Completion date
October 1, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease(ckd), nephrectomy, renal cell carcinoma (kidney cancer), renal cell carcinoma (rcc)